



## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

03678.0064.CPUS02

APPLICATION NO.

10/814,007

APPLICANT

Jose L. BOYER, et al.

FILING DATE

30 March 2004

GROUP

1623

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PL	1.	3,321,463	05-23-67	Moffatt, et al.	260	211.5	03-17-65
	2.						
	3.						
	4.						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	5.							
	6.							
	7.							
	8.							

## OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, Etc.)

PL	9.	Moffatt, et al., "Nucleoside polyphosphates...", Journal of the American Chemical Society (1958), 80, 3756-61.
	10.	
	11.	
	12.	
	13.	
	14.	
	15.	
	16.	
	17.	

*Patent Law* 9-29-05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary) <b>PTO FORM 1449</b>	ATTORNEY DOCKET NO. <b>03678.0064.CPUS02</b>	APPLICATION NO. <b>10/814,007</b>
	APPLICANT <b>BOYER, et al.</b>	
	FILING DATE <b>March 30, 2004</b>	GROUP <b>Not yet Assigned</b>

U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>PL</i>		<b>US 4,621,076</b>	<b>11/04/86</b>					


FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>PL</i>	1.	<b>WO 99/61012</b>	<b>12/02/99</b>	<b>PCT</b>				
	2.	<b>WO 89/04321</b>	<b>05/18/89</b>	<b>PCT</b>				
<i>↓</i>	3.	<b>GB 1407903</b>	<b>10/01/75</b>	<b>United Kingdom</b>				
<i>PL</i>	4.	<b>International Search Report PCT/US01/41818</b>	<b>03/11/02</b>	<b>PCT</b>				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
<i>PL</i>	5.	<b>Hamilton, A. et al., "Design of Substrate-Site-Directed Inhibitors of Adenylate Kinase and Hexokinase. Effect of Substrate Substituents on Affinity for the Adenine Nucleotide Sites", <i>J. Med. Chem.</i>, 19:1371-1377 (1976)</b>
	6.	<b>Hiratsuka T., "Affinity Labeling of the Myosin ATPase with Ribose-Modified Fluorescent Nucleotides and Vanadate", <i>J. Biochem.</i>, 96:147-154 (1984)</b>
	7.	<b>Martin, P. et al., "Structure-Activity Studies of Analogs of <math>\beta,\gamma</math>-Methylene-ATP at <math>P_{2x}</math>-Purinoceptors in the Rabbit Ear Central Artery", <i>Drug Development Research</i>, 36: 153-165 (1995)</b>
	8.	<b>Metzker, M. et al., "Termination of DNA synthesis by novel 3'-modified-deoxyribonucleoside 5'-triphosphate", <i>Nucleic Acids Research</i>, 22:4259-4267 (1994)</b>
	9.	<b>Pelicano, H. et al., "Study of the substrate-binding properties of bovine liver adenosine kinase and inhibition by fluorescent nucleoside analogues", <i>Eur. J. Biochem.</i>, 248:930-937 (1997)</b>
<i>✓</i>	10.	<b>Richard, J. and Frey, P.A., "Stereochemical Course of Thiophosphoryl Group Transfer Catalyzed by Adenylate Kinase", <i>J. Am. Chem. Soc.</i>, 100:7757-7758 (1978)</b>
<i>PL</i>	11.	<b>Sekine, M. et al., "New Type of Chemical Oxidative Phosphorylation: Activation of Phosphonate Function by Use of Triisopropylbenzenesulfonyl Chloride", <i>Tetrahedron Letters</i>, 1145-1148 (1997)</b>


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Patm Ser 29 9-30-05*

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>  <b>PTO FORM 1449</b>	ATTORNEY DOCKET NO. 03678.0064.CPUS02	APPLICATION NO. 10/814,007
	APPLICANT BOYER, et al.	
	FILING DATE March 30, 2004	GROUP Not yet Assigned

PK	12.	Zatorski, A. et al., "Chemical Synthesis of Benzamide Adenine Dinucleotide: Inhibition of Inosine Monophosphate Dehydrogenase (Types I and II)", <i>Journal of Medicinal Chemistry, American Chemical Society</i> , <b>39</b> :2422-2426 (1996)
EXAMINER 		DATE CONSIDERED <u>9-29-05</u>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary) <b>PTO FORM 1449</b> 	ATTY. DOCKET NO. 03678.0064.CPUS02	APPLICATION NO. 10/814,007
	APPLICANT Jose L. BOYER, et al.	
	FILING DATE 30 March 2004	GROUP

U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
PL	1. *	5,049,550	09/17/91	Zamecnik	514	47	11/21/88	
	2. *	5,654,285	08/05/97	Ingall, et al.	514	47	06/06/95	
	3. *	5,681,823	10/28/97	Kim, et al.	514	47	05/02/96	
	4. *	5,721,219	02/24/98	Ingall, et al.	514	47	08/09/95	
	5. *	5,747,496	05/05/98	Cox, et al.	514	258	07/04/96	
	6. *	5,814,609	09/29/98	Markland, Jr. et al.	514	12	11-08-96	
	7. *	5,837,861	11/17/98	Pendergast, et al.	536	25.6	02/10/97	
	8. *	5,900,407	05/04/99	Yerxa, et al.	514	47	02/06/97	
	9. *	5,955,447	09/21/99	Ingall, et al.	514	47	08/28/97	
	10. *	6,166,022	12/26/00	Brown, et al.	514	258	07/15/98	
	11. *	6,323,187	11/27/01	Yerxa, et al.	514	51	05/21/99	
	12.	6,348,589	02/19/02	Pendergast, et al.	536	25.6	02/06/98	
PL	13.	6,596,725	07/22/03	Peterson, et al.	514	25.6	01/30/01	
FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
PL	14. *	WO 92/01673	07/11/91	PCT			X	
	15. *	WO 92/17488	10/15/92	PCT			X	
	16. *	WO 94/08593	28/04/94	PCT			X	
	17. *	WO 94/18216	08/18/94	PCT			X	
	18. *	WO 97/03084	01/30/97	PCT			X	
	19. *	WO 97/29456	21/08/97	PCT			X	
	20. *	WO 98/03182	29/01/98	PCT			X	
	21. *	WO 98/28300	07/02/99	PCT			X	
	22. *	WO 98/34593	13/08/98	PCT			X	
PL	23. *	WO 99/01138	14/01/99	PCT			X	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Patric Lew*

9-29-05

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary) <b>PTO FORM 1449</b>	ATTY. DOCKET NO.	APPLICATION NO.
	03678.0064.CPUS02	10/814,007
	APPLICANT	
	Jose L. BOYER, et al.	
	FILING DATE	GROUP
	30 March 2004	

PL	24. *	WO 99/32085	01/07/99	PCT	<input checked="" type="checkbox"/>	X	
	25. *	WO 00/33080	06/08/00	PCT	<input checked="" type="checkbox"/>	X	
	26. *	WO 00/34283	06/15/00	PCT	<input checked="" type="checkbox"/>	X	
	27. *	WO 00/39145	06/07/00	PCT	<input checked="" type="checkbox"/>	X	
	28. *	WO 00/50024	31/08/00	PCT	<input checked="" type="checkbox"/>	X	
	29. *	WO 01/19826	03/22/01	PCT	<input checked="" type="checkbox"/>	X	
↓	30.	WO 01/39781	07/06/01	PCT	<input checked="" type="checkbox"/>	X	
PL	31. *	WO 01/36421	05/25/01	PCT	<input checked="" type="checkbox"/>	X	

**OTHER REFERENCES**

(Including Author, Title, Date, Pertinent Pages, Etc.)

PL	32. *	Alessi, D. et al., "Synthesis and Properties of a Conformationally Restricted Spin-Labeled Analog of ATP and Its Interaction with Myosin and Skeletal Muscle" <i>Biochemistry</i> (1992), 31(34), 8043-54.
	33. *	Antiplatelet Trialists' Collaboration., "Collaborative overview of randomised trials of antiplatelet therapy-I : Prevention of Death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients," <i>Br. Med. J.</i> 308: 81-106 (1994)
	34. *	Antiplatelet Trialists' Collaboration., "Collaborative overview of randomised trials of antiplatelet therapy-II : Maintenance of Vascular graft or arterial patency by antiplatelet therapy," <i>Br. Med. J.</i> 308: 159-168 (1994)
	35. *	Antman, E, for The TIMI 9a investigators, "Hirudin in Acute Myocardial Infarction," <i>Circulation</i> , 90(4):1624-1630 (1994)
	36. *	Bernat, A., et al., "Effect of Various Antiplatelet Agents on Acute Arterial Thrombosis in the Rat," <i>Thromb. Haemostas.</i> (1993) 70(5):812-816
	37. *	Bujalowski, W. et al., "Structural Characteristics of the Nucleotide-Binding Site of <i>Escherichia coli</i> Primary Replicative Helicase DnaB Protein. Studies with Ribose and Base-Modified Fluorescent Nucleotide Analogs" <i>Biochemistry</i> (1994), 33(15), 4682-94.
	38. *	Bush, L., et al., "Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries," <i>Circulation</i> 69(6):1161-1170, (1984)
	39. *	Cardullo, R. A. et al., "Synthesis, Purification, and Characterization of 2,4,6-Trinitrophenyl-UDP-galactose: A Fluorescent Substrate for Galactosyltransferase" <i>Analytical Biochemistry</i> (1990), 188(2), 305-9.
↓	40. *	Carvalho-Alves, P. et al., "Stoichiometric Photolabeling of Two Distinct Low and High Affinity Nucleotide Sites in Sarcoplasmic Reticulum ATPase" <i>Journal of Biological Chemistry</i> (1985), 260(7), 4282-7.
PL	41. *	Chapal, J. et al., "Comparative effects of adenosine-5'-triphosphate and related analogs on insulin secretion from the rat pancreas" <i>Fundamental &amp; Clinical Pharmacology</i> (1997), 11(6), 537-545.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Patricia Lee* 9-30-05

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)  <b>PTO FORM 1449</b>	ATTY. DOCKET NO. 03678.0064.CPUS02	APPLICATION NO. 10/814,007
	APPLICANT Jose L. BOYER, et al.	
	FILING DATE 30 March 2004	GROUP

PL	42. * Folts, J. et al., "Platelet Aggregation in Partially Obstructed Vessels and its Elimination with Asprian," <i>Circulation</i> <b>54</b> (3):365-370 (1976)
	43. * Frederick, L.G., et al., "The Protective Dose of the Potent GPIIb/IIIa Antagonist SC-54701A is Reduced When Used in Combination with Asprian and Heparin in a Canine Model of Coronary Artery Thrombosis," <i>Circulation</i> <b>93</b> (1):129-134 (1996)
	44. * Geiger, J., et al., "Specific Impairment of Human Platelet P2Y ac ADP Receptor-Mediated Signaling by the Antiplatelet Drug Clopidogrel," <i>Arterioscler. Thromb. Vasc. Biol.</i> <b>19</b> :2007-2011 (1999)
	45. * Hass, W., et al., "A Randomized Trial Comparing Ticlopidine Hydrochloride with Asprian for the Prevention of Stroke for High-Risk Patients," <i>N. Engl. J. Med.</i> , <b>321</b> (8):501-507 (1989)
	46. * Herbert, J.M. et al., "Inhibitory Effect of Clopidogrel on Platelet Adhesion and Intimal Proliferation After Arterial Injury in Rabbits," <i>Arterioscl. Thromb.</i> (1993) <b>13</b> (8):1171-1179
	47. * Hiratsuka, Toshiaki, "Biological Activities and Spectroscopic Properties of Chromophoric and Fluorescent Analogs of Adenine Nucleoside and Nucleotides, 2',3'-O-(2,4,6-Trinitrocyclohexadienylidene) Adenosine Derivatives" <i>Biochimica et Biophysica Acta</i> (1982), <b>719</b> (3), 509-17.
	48. * Hiratsuka, Toshiaki, "Monitoring the Myosin ATPase Reaction Using a Sensitive Fluorescent Probe: Pyrene-Labeled ATP" <i>Biophysical Journal</i> (1997), <b>72</b> (2, Pt. 1), 843-849.
	49. * Hourani, et al., The Platelet ADP Receptors Meeting, La Thuile, Italy, March 29-31, 2000
	50. * Humphries, R.G., et al., "Pharmacological profile of the novel P2T-Purinoreceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vitro," <i>Br. J. Pharmacol.</i> <b>115</b> :1110-1116 (1995)
	51. * Ikehara, M. et al., "III. Interaction Between Synthetic Adenosine Triphosphate Analogs and Actomyosin Systems" <i>Biochimica et Biophysica Acta</i> (1965), <b>100</b> (2), 471-8.
	52. * Ikehara, M. et al., "Unusual Rapid Cleavage of Terminal Phosphate Group of N6-Disubstituted Adenosine 5'-Triphosphate (ATP) by Divalent Cation" <i>Biochimica et Biophysica Acta</i> (1964), <b>85</b> (3), 512-515.
	53. * Ingall, A., et al., "Antagonists of the Platelet P2t Receptor: A Novel Approach to Antithrombotic Therapy," <i>J. Med. Chem.</i> <b>42</b> : 213-220 (1999)
	54. * Kim, et al., "Characterization of the Purinergic P <sub>2</sub> Receptors in PC12 Cells," <i>Journal of Biological Chemistry</i> (1994), <b>269</b> :6471-6477.
	55. * Kwiatkowski, A. et al., "Mapping of the Adenosine 5'-Triphosphate Binding Site of Type II Calmodulin-Dependent Protein Kinase" <i>Biochemistry</i> (1987), <b>26</b> (24), 7636-40.
	56. * Lazarowski, E., et al., "Pharmacological selectivity of the cloned human P2u-purinoreceptor: potent activation by diadenosine tetraphosphate," <i>Brit. J. Pharm.</i> <b>116</b> :1619-1627 (1995)
V	57. * L��kstr��m, J and William R. Bell, "Asprian in the Prevention of Thrombosis," <i>Medicine</i> <b>70</b> (3):161-178 (1991)
PL	58. * Lowe, G. et al., "Evidence of a Dissociative S <sub>N</sub> 1(P) Mechanism of Phosphoryl Transfer by Rabbit

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Aten Len* 9-29-05

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)  <b>PTO FORM 1449</b>	ATTY. DOCKET NO. 03678.0064.CPUS02	APPLICATION NO. 10/814,007
	APPLICANT Jose L. BOYER, et al.	
	FILING DATE 30 March 2004	GROUP

PL	Muscle Pyruvate Kinase" <i>Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry</i> (1972-1999) (1978), (12), 1622-30.
PL	59. * Marian, M., "Acetyl Derivatives of Nucleoside 5'-Triphosphates. I." <i>Microchemical Journal</i> (1984), 29(2), 219-27.
	60. * Mayer, I. et al., "Interaction of Fluorescent Adenine Nucleotide Derivatives with the ADP/ATP Carrier in Mitochondria. 1. Comparison of Various 3'-O-Ester Adenine Nucleotide Derivatives" <i>Biochemistry</i> (1984), 23(11), 2436-42.
	61. * Mickelson, J.K., et al., "Antiplatelet Antibody [7E3 F(ab') <sub>2</sub> ] Prevents Rethrombosis After Recombinant Tissue-Type Plasminogen Activator-Induced Coronary Artery Thrombolysis in a Canine Model," <i>Circulation</i> 81(2):617-627 (1990)
	62. * Murataliev, M. et al., "Interaction of mitochondrial F <sub>1</sub> -ATPase with trinitrophenyl derivatives of ATP. Photoaffinity labeling of binding sites with 2-azido-2',3'-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate" <i>European Journal of Biochemistry</i> (1995), 232(2), 578-85.
	63. * Neuhaus, K. L. et al., "Safety Observations from the Piolet Phase of the Randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) Study," <i>Circulation</i> , 90(4): 1638-1642 (1994)
	64. * Oliveira, C. R. G. et al., "Interaction of Spin-Labeled Nucleotides with Sarcoplasmic Reticulum Adenosinetriphosphatase" <i>Biochemistry</i> (1988), 27(16), 5923-7.
	65. * Olivier, K., et al., "Acute Safety and Effects on Mucociliary Clearance of Aerosolized Uridine 5' - Triphosphate + Amiloride in Normal Human Adults," - <i>Am. J. Respir. Crit. Care Med.</i> 154:217-223 (1996)
	66. * Quinn, M and Desmond J. Fitzgerald, "Ticlopidine and Clopidogrel," <i>Circulation</i> 100(15):1667-1672 (1999)
	67. * Ray, S. et al., "Microenvironment at the Substrate Binding Subsite of the Active Site of UDPglucose 4-Epimerase from <i>Kluyveromyces Fragilis</i> Using a Fluorescent Analog of UMP" <i>Indian Journal of Biochemistry &amp; Biophysics</i> (1992), 29(2), 209-13.
	68. * Romson, J., et al., "Electrical Induction of Coronary Artery Thrombosis in the Ambulatory Canine: A model for IN VIVO Evaluation of Anti-Thrombotic Agents," <i>Thromb. Res.</i> 17:841-853 (1980)
	69. * Seebregts, C. et al., "2',3'-O-(2,4,6-Trinitrophenyl)-8-Azido-adenosine Mono-, Di-, and Triphosphates as Photoaffinity Probes of the Ca <sup>2+</sup> -ATPase of Sarcoplasmic Reticulum. Regulatory/Superfluorescent Nucleotides Label the Catalytic Site with High Efficiency" <i>Journal of Biological Chemistry</i> (1989), 264(4), 2043-52.
	70. * Shebuski, R., et al., "Acceleration of Recombinant Tissue-Type Plasminogen Activator-Induced Thrombolysis and Prevention of Reocclusion by the Combination of Heparin and the Arg-Gly-Asp-Containing Peptide Bitistatin in a Canine Model of Coronary Thrombosis," <i>Circulation</i> 82(1):169-177 (1990)
↓	71. * Soslau, G. et al., "Aggregation of Human and Canine Platelets: Modulation by Purine Nucleotides" <i>Thrombosis Research</i> (1993), 72(2), 127-37.
PL	72. * Thoenges D. et al., "Tight Binding of Bulky Fluorescent Derivatives of Adenosine to the Low Affinity E <sub>2</sub> ATP Site Leads to Inhibition of Na <sup>+</sup> /K <sup>+</sup> -ATPase. Analysis of Structural Requirements of

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*John Lee* 7-29-05

<p align="center"><b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)</p> <p align="center"><b>PTO FORM 1449</b></p>	ATTY. DOCKET NO. 03678.0064.CPUS02	APPLICATION NO. 10/814,007
	APPLICANT Jose L. BOYER, et al.	
	FILING DATE 30 March 2004	GROUP

K		Fluorescent ATP Derivatives with a Koshland-Nemethy-Filmer Model of Two Interacting ATP Sites" <i>Journal of Biological Chemistry</i> (1999 Jan 22), 274(4), 1971-8.
J	73. *	Tschopp, J.F., et al., "Inhibition of coronary artery reocclusion after thrombolysis with an RGD-containing peptide with no significant effect on bleeding time," <i>Coron. Artery Dis.</i> 4:809-817(1993)
J	74. *	Vigne, P. et al., "Benzoyl ATP Is an Antagonist of Rat and Human P2Y <sub>1</sub> Receptors and of Platelet Aggregation" <i>Biochemical and Biophysical Research Communications</i> (1999), 256(1), 94-97.
V	75. *	Ward, D. et al., "Photoinactivation of Fluorescein Isothiocyanate-modified Na,K-ATPase by 2'(3')-O-(2,4,6-Trinitrophenyl)8-azidoadenosine 5'-Diphosphate. Abolition of E1 and E2 Partial Reactions by Sequential Block of High and Low Affinity Nucleotide Sites" <i>Journal of Biological Chemistry</i> (1998), 273(23), 14277-14284.
PL	76. *	Weber, M., et al., "Low-Dose Aspirin Verses Anticoagulants for Prevention of Coronary Graft Occlusion," <i>Am. J. Cardiol.</i> 66:1461-1468 (1990)

*Patric Lee*

9-29-05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.